Clarivate report: key branded drugs losing exclusivity in 2021

Posted 23 July 2021

Loss of exclusivity for innovators means opportunity for imitators.

Clarivate Plc, a global leader in providing trusted information and insights to accelerate the pace of innovation, announced the launch of its new report identifying six branded drugs to watch in 2021 that are losing exclusivity in 2021 and beyond that could impact the generics market. The report also flags the antineoplastics therapeutic area, which has several brands expected to lose exclusivity in the next five years.

Download the full report now to learn more about their potential impact on the future of the generics market.

About Clarivate

Clarivate™ is a global leader in providing solutions to accelerate the lifecycle of innovation. Our bold mission is to help customers solve some of the world’s most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of science and intellectual property. We help customers discover, protect and commercialise their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise. For more information, please visit


News & opinion

Member Directory